3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
111
Lung Neoplasms
54
Adenocarcinoma of Lung
10
Breast Neoplasms
9
Small Cell Lung Carcinoma
5
Neoplasms
5
Mesothelioma, Malignant
5
NSCLC
4
Mesothelioma
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Thoracic Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Non-small Cell Lung Cancer Metastatic
2
Lung Diseases
2
Carcinoma, Ovarian Epithelial
2
Advanced Non-Small Cell Lung Cancer
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pleural Effusion, Malignant
1
Pheochromocytoma
1
Paraganglioma, Extra-Adrenal
1
Pancreatic Neoplasms
1
Non-small Cell Lung Cancer Stage â…¡
1
Interventions
Carboplatin
15
Pemetrexed
8
Paclitaxel
6
pembrolizumab
5
osimertinib
4
atezolizumab
4
Gemcitabine
4
Erlotinib Hydrochloride
4
entinostat
3
durvalumab
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
camrelizumab
2
apatinib
2
Vinorelbine
2
Radiosurgery
2
Nivolumab
2
Injections
2
Gefitinib
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
toripalimab
1
taletrectinib
1
sotorasib
1
sintilimab
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
patritumab
1
necitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thoracic Neoplasms
×
Vinorelbine
×
Thoracic
×
Clear all
NCT05583188
2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4
Terminated
5 enrolled
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled